158 related articles for article (PubMed ID: 30278529)
21. Comparison of inflammation biomarkers among chronic obstructive pulmonary disease groups: A cross sectional study.
Yazici O; Gulen ST; Yenisey C; Eryilmaz U; Abas BI; Polatli M
Niger J Clin Pract; 2020 Jun; 23(6):817-824. PubMed ID: 32525117
[TBL] [Abstract][Full Text] [Related]
22. Effects of omega-3 supplementation on quality of life, nutritional status, inflammatory parameters, lipid profile, exercise tolerance and inhaled medications in chronic obstructive pulmonary disease.
Fekete M; Szarvas Z; Fazekas-Pongor V; Lehoczki A; Tarantini S; Varga JT
Ann Palliat Med; 2022 Sep; 11(9):2819-2829. PubMed ID: 35948470
[TBL] [Abstract][Full Text] [Related]
23. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
Devereux G; Cotton S; Barnes P; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Fielding S; Gompertz S; Haughney J; Lee AJ; McCormack K; McPherson G; Morice A; Norrie J; Sullivan A; Wilson A; Price D
Trials; 2015 Jun; 16():267. PubMed ID: 26058585
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of modified Bushen Yiqi formulas (MBYF) as an add-on to formoterol and budesonide in the management of COPD: study protocol for a multicentre, double-blind, placebo-controlled, parallel-group, randomized clinical trial: FB-MBYF Trial.
Kong Q; Cao Y; Gao Z; Sun J; Zhang H; Du Y; Lv Y; Zhou S; Tang Z; Liu B; Dong J
Trials; 2022 Feb; 23(1):143. PubMed ID: 35164853
[TBL] [Abstract][Full Text] [Related]
25. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
26. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
27. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
[TBL] [Abstract][Full Text] [Related]
28. Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H; Soe Z; Moe S
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
[TBL] [Abstract][Full Text] [Related]
29. Effects of comprehensive therapy based on traditional Chinese medicine patterns in stable chronic obstructive pulmonary disease: a four-center, open-label, randomized, controlled study.
Li SY; Li JS; Wang MH; Xie Y; Yu XQ; Sun ZK; Ma LJ; Zhang W; Zhang HL; Cao F; Pan YC
BMC Complement Altern Med; 2012 Oct; 12():197. PubMed ID: 23107470
[TBL] [Abstract][Full Text] [Related]
30. The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis.
Jiang DH; Wang X; Liu LS; Ji DD; Zhang N
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5211-5216. PubMed ID: 29228436
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
32. Effects of YuPingFeng granules on acute exacerbations of COPD: a randomized, placebo-controlled study.
Ma J; Zheng J; Zhong N; Bai C; Wang H; Du J; Li F; Chen Y; Shi Z; Li X; Chen P
Int J Chron Obstruct Pulmon Dis; 2018; 13():3107-3114. PubMed ID: 30323581
[TBL] [Abstract][Full Text] [Related]
33. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
Sin DD; Lacy P; York E; Man SF
Am J Respir Crit Care Med; 2004 Oct; 170(7):760-5. PubMed ID: 15229100
[TBL] [Abstract][Full Text] [Related]
34. Effect of bufei granule on stable chronic obstructive pulmonary disease: a randomized, double blinded, placebo-controlled, and multicenter clinical study.
Guo S; Sun Z; Liu E; Feng J; Fu M; Li Y; Wu Q
J Tradit Chin Med; 2014 Aug; 34(4):437-44. PubMed ID: 25185361
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease.
Li Z; Tian C; Wang X; Wang L
Medicine (Baltimore); 2018 Aug; 97(31):e11684. PubMed ID: 30075564
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
[TBL] [Abstract][Full Text] [Related]
38. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients.
Ozol D; Aysan T; Solak ZA; Mogulkoc N; Veral A; Sebik F
Respir Med; 2005 Dec; 99(12):1494-500. PubMed ID: 15946834
[TBL] [Abstract][Full Text] [Related]
39. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
40. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
